Aligos Therapeutics, Inc
Price
FilingsNewest: 8-K, Material agreementSep 15 →InsidersNo open-market buys or sales.→HoldersDeep Track Capital 7.1%Alyeska Investment 6.6%Sio 5.2%→Financing →PeersClosest companies: LONA, APRE, ALEC→
From the filings
Figures
- Revenue
- $3.7Mlast 12 months
- Net income
- −$76.0Mlast 12 months
- Operating cash flow
- −$84.7Mlast 12 months
- Cash and equivalents
- $30.4Mat the last balance sheet
- Shares outstanding
- 6.2M shareson issue